Introduction: Data is limited for concurrent capecitabine-radiotherapy (CCRT) in primary breast cancer. We evaluated outcomes and toxicities of patients at high risk of locoregional recurrence receiving adjuvant CCRT. Methods: Ten non-metastatic breast cancer patients receiving concurrent treatment were reviewed retrospectively. Capecitabine was given during and after radiation. Toxicity was reviewed using weekly on-treatment visit and follow-up notes. Results: All patients had stage II-III disease. Four patients had grade 3 skin toxicity during radiation. Capecitabine and RT-related toxicity breaks occurred for 5 and 0 patients, respectively. At 1-month follow-up, 9 patients recovered from acute toxicities sufficiently to start adjuvant capecitabine. At 25 months median follow-up, 1 patient had synchronous local recurrence and distant metastasis (DM), while 3 patients had DM only. Conclusions: Use of CCRT for breast cancer was associated with significant acute grade 3 dermatitis, however, all patients successfully completed their radiation course without interruption.
Introduction
High-risk breast cancer (HRBC), defined as bulky, invasive disease with skin, chest wall and nodal involvement, is composed mainly of stage II-III diagnoses. Five-year survivals are approximately 70%-48% for stage IIB-IIIB disease [1, 2] .
Standard of care for HRBC includes neoadjuvant chemotherapy (NAC) followed by surgery and adjuvant radiotherapy (RT) [3, 4, 5] . Adjuvant RT is associated with improved loco-regional control (LRC), breast-cancer specific mortality, disease-free survival (DFS), and overall survival (OS) [6] [7] [8] [9] [10] [11] .
Capecitabine has been used with increasing frequency for the treatment of metastatic breast cancer [12, 13] . Multiple investigators have reported on the use of concurrent capecitabine-RT (CCRT) for metastatic or recurrent breast cancer [14] [15] [16] [17] [18] . Factors predictive of response to capecitabine with or without paclitaxel, include single-organ metastasis, ER-positivity and Her-2-negativity [19] [20] [21] [22] . A meta-analysis has shown an overall response with capecitabine-based chemotherapy versus capecitabine-free chemotherapy. OS was found to be non-significantly higher for capecitabine-based chemotherapy [12] . In randomized studies of non-metastatic patients undergoing NAC regimens, capecitabine was well-tolerated with mixed results
Ivyspring
International Publisher regarding DFS [23, 24] .
To our knowledge, there are no reports of the tolerability, toxicity and efficacy of single-agent capecitabine with RT for primary HRBC. We evaluated primary HRBC patients treated with NAC followed by CCRT after surgery. Acute and late toxicity, local recurrence (LR), distant metastases (DM), and OS are reported at a median follow-up of 25 months.
Materials and Methods
Records of HRBC patients treated between 2009-2014 were evaluated retrospectively after study approval by the institutional review board. Inclusion criteria were non-metastatic, locally-advanced and biopsy-proven HRBC receiving CCRT, with cT2-4N0-3 or pT1c-2N0-3 based on the American Joint Committee on Cancer version7. High-risk disease was defined based on minimal response to neoadjuvant therapy in patients with stage II-III disease.
We identified ten patients treated with CCRT. All patients received NAC or neoadjuvant endocrine therapy. All patients were deemed operable by the treating surgeon. The use of CCRT was at the discretion of the treating medical and radiation oncologists. Indications included persistently elevated ki-67 levels at the time of surgery (>50%), significant axillary tumor burden (>50% dissected lymph nodes involved) and persistent disease at the primary site.
Chemotherapy
Capecitabine was 1000mg p.o. twice a day (b.i.d.) for 2 cycles during RT and 4 cycles of 1000-1500mg p.o. b.i.d. after RT completed. A cycle was defined as 2 weeks on treatment then 1 week off. Capecitabine was discontinued at the discretion of the treating radiation oncologist based on toxicity during CCRT.
Radiation Therapy
RT was 45-50.4Gy in 1.8-2Gy daily fractions to the chest wall or breast and regional lymph nodes followed by a 10-14Gy boost to the scar or lumpectomy cavity. 3D-conformal RT was delivered with tangential fields and a supraclavicular field, with inclusion of internal mammary nodes in 2 cases using wide tangent fields.
Endpoints
Acute toxicity was defined as occurring at treatment start to 3 months after completion of treatment. Late radiation effects occurred > 3 months after completion of treatment. End-points evaluated were acute and late toxicity grade per Common Terminology Criteria for Adverse Events version 4.0, local recurrence free survival (LRFS), distant recurrence free survival (DRFS), and OS. Distant disease was defined as disease found beyond the treated breast and axilla on follow-up imaging or clinical exam.
Follow-up
All patients were evaluated weekly during CCRT, 1-month after completion of RT, and routinely thereafter. Toxicity was assessed by review of weekly on-treatment (OTV) and follow-up notes.
Statistical Methods
The Fisher exact test was used to assess the association between toxicity at the last treatment and toxicity at 1-month and 6-month follow-up. Kaplan-Meier curves were used to calculate the LRFS and DRFS. The log-rank test was used to compare LRFS and DRFS between patients who received capecitabine as planned and those in whom capecitabine was held. OS for the cohort was calculated and plotted using Kaplan-Meier curves and death was counted if reported within the electronic medical record.
Results
All patients received neoadjuvant systemic therapy followed by surgery (cytotoxic chemotherapy=9). One patient received neoadjuvant hormonal therapy alone due to a low OncotypeDX score from the biopsy specimen.
Seven patients underwent modified radical mastectomy. One patient had two different primary tumors in the same breast at the time of diagnosis, Luminal B histology and the other Basal histology. Biologic subtype was Luminal B n=9 on immunohistochemistry. Eight patients had residual breast involvement with pT1-2 disease. Seven patients had residual nodal involvement at the time of surgery.
Seven patients with Luminal B disease received adjuvant hormonal therapy. Two patients did not receive adjuvant hormonal therapy because they were lost to follow-up. None of the patients received adjuvant chemotherapy.
Patient and lesion characteristics are provided in Table 1A and B, respectively.
Toxicity during treatment
Three patients developed grade 1 radiation dermatitis, 3 grade 2, 4 grade 3, and none with grade 4. Capecitabine was held for 5 patients due to skin toxicity, of whom 2 patients developed brisk confluent erythema. Four RT plans required modification due to grade 3 skin toxicity; the boost was started early at 44Gy for one patient, the bolus was discontinued for 2 patients, and the internal mammary field was discontinued at 46Gy (planned 50Gy) for 1 patient. No patient required a break from RT.
Toxicity at follow-up
We evaluated skin toxicity at 1-and 6-month follow-up to see if the effects were acute vs. late. At the 1-month follow-up, 3 patients who had grade 3 toxicity during RT had grade 1 toxicity, with 1 patient having no toxicity. None of the patients who had <grade 3 skin toxicity at the end of treatment had skin toxicity at 1-month follow-up. There were no grade 4 toxicities documented at 1-month follow-up. Nine patients had recovered from their acute toxicities sufficiently to start adjuvant capecitabine by the 1-month follow-up. Patients with ≥grade 3 skin toxicity at the end of treatment were more likely to have skin toxicity at 1-month follow-up compared to patients with <grade 3 toxicity (p=0.03, Table 2 ).
Follow-up at 6-months was available for 7 patients. One patient had no reported toxicity, 3 had grade 1 chest wall pain, and 3 had grade 1 lymphedema. Three patients who had grade 3 skin toxicity at the end of treatment had follow-up data at 6-months. Two patients had grade 1 lymphedema and 1 had grade 1 chest wall pain. Four patients had <grade 3 skin toxicity at the end of treatment had 6-month follow-up. Of these patients, 1 had no toxicity, 2 had grade 1 chest wall pain, and 1 had grade 1 lymphedema. Patients with ≥grade 3 skin toxicity at the end of treatment were not more likely to have skin toxicity at the 6-month follow-up compared to patients with <grade 3 toxicity (p=1.0, Table 2) .
At a median follow-up of 25 months, there were no documented cases of pneumonitis or brachial plexopathy. Table 3 includes the major toxicities seen at last OTV, 1, 3, and 6-month follow-up.
Disease outcomes
At a median follow-up of 25 months, one patient had synchronous LR and DM while three patients had DM only. No patients had isolated LR. The 2-year LRFS for the entire cohort was 87% (Figure 1a) , and the DRFS was 75% (Figure 2a ). The disease outcomes of patients for whom capecitabine was held during RT vs not held showed no difference in either LRFS (p=0.32) or DRFS (p=0.76) (Figures 1b and 2b,  respectively) . All patients are currently alive with 2-year OS 100%. 
Discussion
Patients with residual disease following neoadjuvant chemotherapy are at significant risk of locoregional recurrence [25] . Therefore, this population may warrant intensification of adjuvant therapy. In this study, we analyzed outcomes in patients with HRBC who received adjuvant CCRT. Seven patients had residual nodal disease at the time of surgery after neoadjuvant systemic therapy.
Distant recurrence was the predominant mode of failure in our series with one patient failing locally and distantly and 3 patients failing distantly only.
In our study, 9 patients had recovered from their acute skin toxicity at the 1-month follow-up to start adjuvant capecitabine. A current phase II study at MD Anderson Cancer Center assessing neoadjuvant capecitabine and RT in advanced breast cancer is anticipated for primary completion in 2017 and should help assess the utility and potential toxicities of this regimen.
Capecitabine has demonstrated activity in metastatic and inoperable breast cancer and has been used as a radiosensitizer with concurrent RT in other disease sites [26] . We had higher than expected acute dermatitis with adjuvant CCRT but limited late toxicity. Given our low numbers and limited long-term follow-up, we must be careful to limit generalizations regarding late toxicity. There were, however, no unanticipated late toxicities noted; this includes one patient who underwent tissue expander placement followed by an implant reconstruction 2 years after completion of RT and another patient who had pre-existing implants at the time of RT who had no evidence of capsular contracture at 2-year follow-up.
Conclusions
CCRT appears to be associated with increased acute dermatitis but acceptable late toxicity. Further prospective studies are warranted to elucidate whether adding chemotherapy to adjuvant RT in HRBC will result in improved outcomes.
